Depression News

A large proportion of adolescent patients treated with isotretinoin for acne had a history of a psychiatric diagnosis, but most were not diagnosed with additional psychiatric diagnoses or symptoms during treatment, according to a study.

Alto Neuroscience Inc. has initiated a phase 2 study to determine the safety, tolerability and pharmacokinetics of ALTO-203 among patients with major depressive disorder and to evaluate its effectiveness as an antidepressant.

A Houston-area neurohealth company announced completion of a full production test run, along with usability, feasibility design verification and electrical safety testing for its noninvasive, frequency-based deep brain stimulation device.

ATLANTA — Younger women with a diagnosis of anxiety or depression are at markedly higher risk for developing conditions that increase CVD risk, such as hypertension, hyperlipidemia and diabetes, researchers reported.

Artificial intelligence language models were able to accurately predict the severity of depression symptoms based on social media posts among white people but not among Black people, according to a recent study.

According to results published in Orthopedics, patients with vs. without psychiatric diagnoses, such as depression, bipolar disorder, anxiety disorder and schizophrenia, had similar clinical outcomes after fracture-related infection.

The long-term adjudicated suicidal ideation and behavior rate in patients with psoriasis treated with bimekizumab was low and within general psoriasis population ranges, according to a study.

The risk for mental health conditions and self-harm or suicide was higher among partners and adult offspring of stroke survivors vs. the general population and family of myocardial infarction survivors, according to a study in Denmark.

Women are not universally at risk for depressive symptoms during menopause transition, but providers should be aware of risk factors and treat mental health disorders promptly, according to a review published in The Lancet.

Neurocrine Biosciences Inc. announced a phase 1 study to evaluate an investigational neuropsychiatric therapy in healthy adults, as well as commencement of dosing in a phase 2 study of a novel oral compound for major depressive disorder.